Job description
Tenure track 2024 (chaire de professeur junior)

**Faculté de Santé**
- **Department**: Institut Pierre Louis d’Épidémiologie et de Santé Publique
- **Location**: Sorbonne Université, Hôpital Saint Antoine, Hôpital la Pitié Salpêtrière

**Job Identification**
- **Discipline**: Epidemiology and biostatistics with applications to infectious diseases
- **Corresponding CNU sections**: 46 (Public Health), sub section 4604 (biostatistics, medical informatics, communication technologies), sub section 4601 (epidemiology, health economics, prevention)
- **Job title**: Tenure track
- **Duration of the contract**: 3 years
- **Quotity**: 100%
- **The minimum monthly remuneration is fixed by decree at 3,443.50 euros gross**

**Etat du poste**: open

**Profil**
- Epidemiology and biostatistics - infectious diseases

**Job Profile**
Cliquez ou appuyez ici pour entrer du texte.

**Education**
**Summary of the teaching project:**
IPLESIP is strongly committed to academic and professional training and coordinates the doctoral school in public health (ED393), the master's degree in public health and other training courses in epidemiology and biostatistics at SU. Thanks to his or her skills in clinical epidemiology, biostatistics and infectious diseases, the successful candidate will be able to contribute to the biostatistics and epidemiology courses in the various Masters programmes, 'Statistics, modelling and health data sciences (SMSDS)' and 'Clinical epidemiology and pharmaco-epidemiology (ECLIPE)'. In particular, he will develop a course in the clinical epidemiology of infectious diseases for the M2. He will supervise Masters and PhD students. He will be encouraged to submit a doctoral proposal to ED 393, which will be open to applications for a doctoral contract at SU.

**Funding:**
- ANR package: 200 000 €
- Total: 200 000 €

**Use of the ANR package:**
- Post-doctorant: 110 000 €
- Operating costs (missions, conferences, ...) : 90 000 €

**Research**
**ERC scientific theme**: Biology and health

**Plant strategy:**
This CPJ reinforces the themes in which SU has demonstrated its leadership and which are at the heart of its establishment project, and in particular the "global approach to health" axis of the ExcellencES SOUND project (PIA 2012). The training and research activities associated with this CPJ are geared to the contributions that can be made to respond collectively to society's challenges. The activities of the IPLESIP laboratory concern public health epidemiology, and include clinical, population and social epidemiology, pharmaco-epidemiology, biostatistics, statistical and mathematical modeling, clinical research, methodology and clinical trials, the relationship between environment and health, social determinants of health and health care organizations. In terms of applications, IPLESIP focuses on
communicable diseases (influenza, HIV infection, viral hepatitis, etc.), nosocomial and emerging infections, and chronic diseases (chronic inflammatory diseases, cardiovascular diseases, psychiatric diseases). IPLESP also provides national health authorities with healthcare data to guide public health policy on these chronic infections.

IPLESP is proposing a CPJ in the field of clinical epidemiology of chronic hepatitis B and identification of biomarkers of progression. Multidisciplinary expertise in clinical epidemiology and biostatistics is required to carry out this study.

Host laboratory strategy:
IPLESP brings together all the epidemiology and public health research strengths at SU. The CLEPIVIR team is one of 6 teams focusing on chronic viral diseases and their long-term prognosis. It coordinates large cohorts on these infections, particularly HIV and viral hepatitis, and has a strong biostatistical component. CPJ's scientific project concerns the clinical epidemiology of hepatitis B and the identification of biomarkers of progression by combining multiple data sources (cohorts, biological data and medico-administrative data, etc.). It is in line with the team's priority objectives of estimating the long-term consequences of chronic viral infections and their therapeutic management. It also fits in with IPLESP's strategy of valorizing cohort data and developing holistic approaches to health issues.

Summary of scientific project:
The project focuses on identifying long-term prognostic factors in patients with chronic hepatitis B and estimating the impact of new treatments and management strategies. It uses data from the Hepather (2012-2023) and Hepat-B cohorts, coordinated by IPLESP. In 2023, 5,294 patients have been followed up since 2012, and for 85% of them, all data on consumption of ambulatory care, hospitalizations and causes of death are available, thanks to chaining with the SNDS. In addition to the clinical data, this project has a biothèque built up at inclusion (2012-2015) and 2 biological collections are planned (2024-2028). The chairholder will implement analyses of these voluminous and complex data, in particular longitudinal analyses involving emulation of trials or other causal methods for observational data, to understand the progression of hepatitis B, the role of treatments and long-term risks.

International attractiveness strategy:
The scientific project on which this chair is based is already the subject of numerous national and international collaborations, and opens up opportunities to host foreign students (Masters, Doctorate, Post-doctorate), including from international training programs. At European level, we have established collaborations with the H2020 IP-CureB program, which is evaluating strategies for treating chronic hepatitis B with new molecules; the team is a member of the HBV Cure task force (Fabien Zoulim, U1052, Lyon), one of whose aims is to identify prognostic biomarkers for functional cure of hepatitis B - a central objective of this chair; we are collaborating with teams in England (Patrick Kennedy, Bart Health NHS Trust, London) and Greece (Georgios Papatheodoridis, National and Kapodistrian University of Athens, Athens) on various projects involving the pooling of data to increase the power of studies.

Scientific distribution:
The aim is for the CPJ winner to become a world leader in the clinical epidemiology of hepatitis B, which affects 300 million people and is responsible for around 800,000 deaths a year. As with all research topics, the results obtained in the context of the CPJ will be published in international journals and presented at international conferences and congresses. As this is fundamental research, no knowledge transfer activities other than publications or scientific mediation are envisaged.

In research, the winner will have the opportunity to interact with researchers at IPLESP and partner laboratories. He or she will raise the profile of the discipline, the laboratory and the University by taking part in international conferences and workshops to present results. As a supervisor, he or she will be able to recruit a post-doctoral or doctoral student thanks to the "package" provided, and will also be able to co-supervise students and trainees from the research team. As a collective investment, the winner will be involved in communicating with the general public.

Science and society:
The end products of the IPLESP are not only peer-reviewed scientific articles, but also the production of relevant information to guide changes in clinical practice and healthcare organizations, and to advise public health and political decision-makers, patient organizations and the general public. In this context, and
depending on the subject, original results obtained by the Chairholder are intended to be communicated to the general public or patient associations via the mainstream media.

<table>
<thead>
<tr>
<th>Laboratory</th>
<th>Sigle (UMR, UMRS, etc.)</th>
<th>N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institut Pierre Louis d’Épidémiologie et de Santé Publique</td>
<td>UMRS</td>
<td>1136</td>
</tr>
</tbody>
</table>

**Application procedure**

Applications are open from June 1st 2024 10:00 am (Paris time) to July 1st 2024 4:00 pm (Paris time). Applications must be submitted on the Galaxie website. Candidates who do not have access to this Galaxie application (in particular non-French candidates) may exceptionally submit the complete application electronically according to the established schedule and procedures. Send the application files to pascale.bechu@sorbonne-universite.fr with the subject "Candidature CPJ".

The documents to be attached to the application file are set by the decree of February 6, 2023, as amended, concerning the general terms and conditions for the transfer, secondment and recruitment by competition of lecturers, university professors and junior professors (see in particular Title III - articles 24 to 27 and Title IV - articles 28 to 31).

Candidates who do not hold a doctorate must have their university diplomas, qualifications and titles recognized as equivalent to a doctorate, in accordance with one of the procedures provided for in article 5 of decree no. 2021-1710 of December 17, 2021 concerning the junior professorship contract provided for in article L. 952-6-2 of the Education Code and article L. 422-3 of the Research Code. Any incomplete application by the above-mentioned deadline will be declared inadmissible.

Only candidates who have been selected by the selection committee based on their applications will be invited to an interview, according to a timetable and procedures that will be communicated shortly.

Professional simulation: No.

The aforementioned decree n° 2021-1710 of December 17, 2021 determines the conditions of renewal of the contract, the modalities of assessment, before the tenure, of the scientific value and the aptitude to carry out the missions of each body, the modalities of appointment of the members of the selection and tenure commissions and the conditions of the commitment to serve.

**Contacts**

Research: fabrice.carrat@iplesp.upmc.fr
Education: fabrice.carrat@iplesp.upmc.fr